Publications by authors named "Monia Sisi"

Claim this Profile
C
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
Monia Sisi, Giovanni Vitale, Michele Fusaroli, Mattia Riefolo, Valentina Giunchi

JTO Clin Res Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
Elisa Andrini, Alessandro Di Federico, Monia Sisi, Matteo Rosellini, Arianna Palladini

Immunotherapy· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Monia Sisi, Michele Fusaroli, Andrea De Giglio, Francesco Facchinetti, Andrea Ardizzoni

Target Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution.
Alessandro Di Federico, Elisa Andrini, Monia Sisi, Giacomo Nuvola, Giuseppe Lamberti

Anticancer Drugs· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
Francesco Gelsomino, Francesco Facchinetti, Monia Sisi, Teresa Zielli, Marcello Tiseo

Immunotherapy· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi

Crit Rev Oncol Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Alessandro Di Federico, Giacomo Nuvola, Monia Sisi, Barbara Lenzi, Elisabetta Nobili

Anticancer Drugs· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Di Federico, Biagio Ricciuti

Future Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis